<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210228050519N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-27</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>The effect of three-component mouthwash (nystatin, aluminum MGS and diphenhydramine), chamomile and mucosamine spray in the treatment of oral mucositis caused by chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of three compounds (nystatin, aluminum ammonia, and diphenhydramine), mouthwash, chamomile, and mucosamine spray in the treatment of chemotherapy-induced oral mucositis in malignancy in children with leukemia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54832</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: All children are admitted to the study according to the inclusion criteria and sampling is done in an accessible and easy way. In this study, randomized block method will be used to randomize the three groups of routine treatment (group A), chamomile mouthwash treatment (group B) and mucosamine spray treatment (group C). Children will be divided into three equal groups (A / B / C) using random allocation. In order to perform random allocation, the randomized blocking method with 6 blocks such as AABBCC, ABBACC, BBAACC, AACCBB, BBCCAA, ACBCAB, etc. will be used, which will have numbers from 1 onwards. Then, by randomly selecting numbers from 1 to n, random sequences of three types of drugs will be identified for the studied samples, Blinding description: In this study, the statistical expert and the evaluator of the outcome are not aware of the type of drug used, so the study is double-blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Severity of oral mucositis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Before starting chemotherapy, all subjects will be taught the correct way to observe oral hygiene, including brushing and flossing. All participants received a three-combination mouthwash (nystatin, aluminum ammojas, and diphenhydramine) as a routine treatment for such children who rolled for 1 minute once a day in the morning (receiving daily mouthwash until the 14th day). After mouthwash, patients do not consume food or fluids for up to 1 hour (group A). Intervention 2: Intervention group: • In the chamomile group, use chamomile mouthwash available in pharmacies for a week, three times a day (morning, noon, night) after brushing. Dilute 15 drops of the solution in 10 cc of water and gargle for one minute and do not eat for an hour after that, and the previous standard treatment of the treating physician will continue except for the use of topical mouthwash (group B). (Receive daily mouthwash until the 14th day). Intervention 3: In the mucosamine group (water, sodium, glanzine, propylene glycol, lysine, leucine and proline) in addition to the three-combination mouthwash, mucosamine is sprayed 3 times a day on the entire mucous membrane of the patient's mouth (group C) (spray received) Daily until the 14th day). No drug interactions have been reported for this drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I have not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Khalil Namazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar aazam (SAW) University Complex Basij Square of the University Complex</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>+98 914 451 3811</telephone>
        <email>namazikhalil44@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>khalil namazi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar aazam (SAW) University Complex Basij Square of the University Complex</address>
        <city>arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>+98 914 451 3811</telephone>
        <email>namazikhalil44@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Full consciousness
Hospitalized in the oncology ward of Arak Children's Hospital
No gum disease
Lack of continuous use of painkillers and drugs
Similar treatment protocol
Minimum age 2 years and maximum 16 years
Having oral mucosa (minimum score 1)
No history of chamomile mouthwash and mucosamine spray</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>16 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Improvement of oral mucosa before randomization</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>موکوزیت دهانی</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Before starting chemotherapy, all subjects will be taught the correct way to observe oral hygiene, including brushing and flossing. All participants received a three-combination mouthwash (nystatin, aluminum ammojas, and diphenhydramine) as a routine treatment for such children who rolled for 1 minute once a day in the morning (receiving daily mouthwash until the 14th day). After mouthwash, patients do not consume food or fluids for up to 1 hour (group A).</i_keyword>
      <i_keyword>Intervention group: • In the chamomile group, use chamomile mouthwash available in pharmacies for a week, three times a day (morning, noon, night) after brushing. Dilute 15 drops of the solution in 10 cc of water and gargle for one minute and do not eat for an hour after that, and the previous standard treatment of the treating physician will continue except for the use of topical mouthwash (group B). (Receive daily mouthwash until the 14th day).</i_keyword>
      <i_keyword>In the mucosamine group (water, sodium, glanzine, propylene glycol, lysine, leucine and proline) in addition to the three-combination mouthwash, mucosamine is sprayed 3 times a day on the entire mucous membrane of the patient's mouth (group C) (spray received) Daily until the 14th day). No drug interactions have been reported for this drug</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of oral mucositis. Timepoint: On the first day (before the intervention), the seventh day and the fourteenth day. Method of measurement: Mucosal severity instrument with a scoring range of 0 to 4.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-17</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Payambar aazam (SAW) University Complex, Basij SQ, Sardasht region Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
